soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results soul trial oral semaglutide cardiovascular

The 68-week treatment period was followed by a 7-week follow-up period during which patients did not receive Wegovy or placebo

Currently, Tirzepatide and Semaglutide are the leading options for weight loss injections

Statistical analysis Statistical analyses were performed by one-way ANOVA followed by Bonferronis post-test for multiple comparisons, as appropriate

Now she gets to share her journey and educate others on how to take back control of their health so they can fully enjoy life with the people they love.

This dual-pathway activity is one reason tirzepatide is often discussed as a stronger option for weight management

Dehydration is a major contributor that many patients overlook